The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study).
 
Rohan Garje
Research Funding - Amgen (Inst); Endocyte/Advanced Accelerator Applications (Inst); Immunomedics (Inst); Pfizer (Inst)
 
Vignesh T. Packiam
Honoraria - CG Oncology
 
Amy Koski
No Relationships to Disclose
 
Mohammed M. Milhem
Honoraria - Array BioPharma; Biontech; Novartis
Consulting or Advisory Role - Array BioPharma; Biontech; Exicure; Novartis
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Michael A. O'Donnell
Consulting or Advisory Role - Abbott/AbbVie; Fidia Pharma USA; Merck; Photocure; Theralase; UroGen pharma; Vaxiion
Research Funding - Abbott (Inst); Photocure (Inst)
Travel, Accommodations, Expenses - Photocure
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics